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Background: Sleep-disordered breathing (SDB) is common after stroke, but it is unclear whether it should
be treated.
Objective: To conduct a randomised controlled trial of continuous positive airway pressure (CPAP) after
stroke.
Methods: Patients with stroke with >30 apnoeas and hypopnoeas per hour ((A+H)/h) with predominant
obstructive sleep apnoea or hypopnoea were randomised to either CPAP treatment or conservative
treatment for 8 weeks. Outcomes were measured blind to treatment allocation at 8 weeks and 6 months
after the stroke. The primary outcome was physical function on the Nottingham Extended Activities of Daily
Living Scale.
Results: Of 658 patients with stroke screened, only 71 (10.7%) were eligible and consented to a sleep
study 14–19 days after stroke. 66 patients completed the sleep study (21 women; mean age 72 years), 33
(50%) had >30 (A+H)/h that were predominantly obstructive. 15 were randomised to CPAP treatment
and 15 to conventional treatment. Despite intensive efforts, objective use of CPAP was poor, averaging
1.4 h a night. CPAP treatment resulted in no significant improvements (p.0.1) in the primary outcome or
in neurological function or sleepiness, and in poorer health status on some measures.
Conclusions: This trial showed no benefit from CPAP treatment, the relevance of the observed detrimental
effects is questionable. Even in our highly selected patients with stroke, use of CPAP was poor. At present,
CPAP treatment should be advocated for patients with stroke only if they have symptoms of SDB.
I
n the past decade, a link between stroke and sleep-
disordered breathing (SDB) has been recognised.
Longitudinal studies have shown that people with SDB
have a greater risk of stroke,1 although this relationship is
partly explained by the association between SDB, obesity and
hypertension. SDB is also common after stroke2–5 and has
been associated with poor outcomes.6–10 Continuous positive
airway pressure (CPAP) treatment improves daytime func-
tion,11 blood pressure12 and cerebral blood flow13 in stroke-
free people with SDB and may reduce their risk of
cardiovascular event.14 The question then arises whether
CPAP treatment in patients with stroke with SDB might
improve outcomes. Martinez-Garcia et al15 showed that
patients with SDB after stroke who complied with CPAP
use had fewer vascular events during follow-up than those
who did not. To reliably determine whether CPAP use
improves outcome, however, we need to conduct randomised
controlled trials (RCTs). There have been few trials of CPAP
use for SDB in patients with stroke, and only one entailed
random allocation to CPAP use or control.16
We conducted an RCT in patients with stroke with SDB to
examine whether CPAP use is beneficial. Specifically, we
hypothesised that nasal CPAP use might improve sleepiness,
fatigue, cognitive function and mood in patients with stroke
with SDB, we also postulated that nasal CPAP might make
this group more compliant with rehabilitation and stabilise
circadian blood pressure in the recovery phase of stroke; thus
CPAP use would result in better functional outcome.
PATIENTS AND METHODS
Recruitment
We approached consecutive patients with stroke admitted to
two acute stroke units in the university hospitals in
Edinburgh, UK from March 2001 until May 2003. The
diagnosis of stroke was confirmed by neurological assess-
ment and computed tomography scans or magnetic reso-
nance images. Ischaemic strokes were classified according to
the Oxford Community Stroke Project.17 Patients were asked
to consent to an initial screening for SDB and, if this was
positive, to be enrolled into an RCT on CPAP use. The local
ethics committee approved the study.
Inclusion criteria were as follows: age 21–90 years; stroke
14–19 days previously; pre-stroke Modified Rankin Score
(2; National Institutes of Health Stroke Score >4.18 We
selected patients at 14–19 days after stroke so that they were
likely to be clinically stable and had had a longer time to
adjust to the stroke, and so greater potential to use nasal
CPAP.
Exclusion criteria were as follows: severe or unstable
medical conditions including dementia; severe dysphasia or
confusion that would inhibit the patient cooperating with the
diagnostic study or CPAP treatment; unusual stroke (eg,
venous infarction, vasculitis, brain tumour, myocardial
infarction); insufficient hand function to use a mask and
no overnight care giver to help.
Baseline assessment and sleep study
Demographic information was collected from case notes.
Between days 14 and 19 after stroke, recruited patients had a
limited sleep study using a validated19 system (Embletta
Abbreviations: ACE, Addenbrooke’s Cognitive Examination; CPAP,
continuous positive airway pressure; EADL, Extended Activities of Daily
Living; HADS, Hospital Anxiety and Depression Scale; IQR, interquartile
range; RCT, randomised controlled trial; SDB, sleep-disordered
breathing
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Portable Diagnostic System, Medcare Flaga, Iceland) incor-
porating nasal pressure, oral thermistor, thoracoabdominal
movement, finger pulse oximetry and body position.
The portable device was programmed to record from 21:00
to 06:00. Data were downloaded on to a computer and scored
manually. As the Embletta Portable Diagnostic System does
not record sleep, the onset of sleep was taken as the onset of
rhythmic stable breathing. The end of the study was taken as
the patient’s or care giver’s report of final awakening time or
continuous movement artefacts without coming back to
regularity of breathing pattern. Apnoeas and hypopnoeas
were scored using standard criteria,20 and the total number of
apnoeas and hypopnoeas per hour in bed after sleep onset
was reported as (A+H)/h.
Baseline assessments were carried out the morning after
the sleep study. They included Stanford Sleepiness Scale, a 7-
point Likert scale21 assessing current sleepiness after stroke,
Epworth Sleepiness Scale assessing pre-stroke sleepiness if
patients were clear and cooperative enough to fill in the
questions, Barthel Index22 indicating their functional inde-
pendence in everyday activities, Hospital Anxiety and
Depression Scale (HADS)23 measuring psychological distress,
and Addenbrooke’s Cognitive Examination (ACE)24 assessing
cognition and allowing derivation of the Mini-Mental State
Examination.25
Randomised trial of nasal CPAP use
Between days 21 and 25 after stroke, patients who had
(A+H)/h >30 with ,30% of events due to central apnoeas or
Cheyne–Stokes respiration were enrolled into our RCT. The
cut-off point>30/h was set to recruit a group of patients with
stroke who had severe SDB.20 Patients were randomly
allocated to receive either 8 weeks of CPAP treatment with
Autoset T (ResMed, SanDiego, California, USA) or conserva-
tive treatment for SDB. Intensive input by a senior sleep
research nurse who was experienced in CPAP treatment was
arranged on day 1, day 3, day 5, week 1, week 2, week 4 and
week 6 of treatment to optimise compliance. The nurse
managed all problems related to mask, machine and
complications of CPAP. The treatment period lasted 8 weeks,
unless the patient asked for CPAP to be withdrawn. Hours of
CPAP usage were downloaded from the machine. Both
groups received advice on weight loss and alcohol avoidance
when appropriate and all drugs and rehabilitation pro-
grammes were maintained as usual.
C-YH identified patients and MV allocated treatment using
sealed opaque envelopes with balanced blocks of six and
delivered the treatment. Thus C-YH was blind to the allocated
treatment and carried out all outcome assessments.
Outcome measures
The Nottingham Extended Activities of Daily Living (EADL)26
Index was chosen as the primary outcome measure for
assessing functional capacity in four domains in terms of
mobility, kitchen, domestic activity and leisure activity. It is
sensitive to change and does not have a ceiling or floor effect,
and so is suitable for use in mild to moderate stroke.
Secondary outcome measures included subscales of EADL,
National Institutes of Health Stroke Score, Barthel Index,
Stanford Sleepiness Scale, ACE and Mini-Mental State
Examination, HADS (anxiety and depression subscales),
MOS Short Form 36 Health Survey and subscales, and
ambulatory blood pressure27—measured using Spacelabs
90207 (Spacelabs, Redmond, Washington, DC, USA). The
blood pressure monitor was programmed to measure every
30 min for 24 h, starting between 14:00 and 15:00. We
defined pressures between 06:00 and 21:59 as occurring
during daytime and those between 22:00 and 05:59 as
occurring during night, corresponding to the schedule of the
stroke wards.
Follow-up
C-YH, a neurologist, conducted two face-to-face interviews.
To ensure blinding to treatment allocation, MV informed the
patient, care giver or nursing staff to hide any CPAP machine
when C-YH visited the patient. All outcomes were recorded in
the 8th week after randomisation. The EADL, Barthel Index
and Short Form 36 Health Survey were measured at
6 months after stroke in both groups.
Sample size
Before the study, we estimated that 40 patients using CPAP
(CPAP group) and 40 controls (undergoing conventional
treatment) were needed for 80% power at 5% significance
level to show 0.57 point standardised mean difference in the
EADL. This was on the basis of outcome data from an RCT of
outpatient occupational therapy for stroke.28
Statistical analyses
These were based on intention to treat. All continuous data
with normal distribution are presented as mean (standard
deviation (SD)) and those without normal distribution as
median (interquartile range (IQR)). Non-parametric tests
were used, including Mann–Whitney’s U test and x2 test
(Fisher’s test if ,20 patients in a category) for between-
group comparisons; p,0.05 was considered significant.
Multiple linear regression and logistic regression were used
to adjust for baseline imbalance. All predictors with p,0.1 in
univariate regression analysis were entered into the model,
and coefficient and confidence interval (CI) were expressed.
Data were statistically analysed by SPSS V.11.0.
RESULTS
Recruitment and demographic characteristics
We screened 658 patients with suspected stroke between
March 2001 and June 2003. Only 96 of 658 patients were
eligible (fig 1). Of the 66 patients who completed their sleep
study, 45 (68%) were men, mean age 72 years, and their pre-
stroke Modified Rankin Scores were 0 in 56, 1 in 7 and 2 in 3
patients. Their median National Institutes of Health Stroke
Scale at 3 weeks after stroke was 6 (IQR 2–10). Of the 66
patients, 60 had first-ever strokes. According to the Oxford
Community Stroke Project classification, 13 patients had
total anterior circulation infarct, 41 had partial anterior
circulation infarct, three had posterior circulation infarct,
four had lacunar infarct and the remaining five had primary
intracerebral haemorrhage. The baseline data of 25 patients
who declined to give informed consent and five patients who
had inadequate sleep studies were not significantly different
from those of recruited patients (p.0.7).
Results of sleep studies
The sleep study analysis had high intrarater (intraclass
correlation coefficient 0.983, p,0.001) and inter-rater relia-
bility (intraclass correlation coefficient 0.977, p,0.001).
(A+H)/h was >30 in 33 patients, >20 in 40, >15 in 46 and
>10 in 56 patients. The median (A+H)/h was 31. All patients
with SDB had predominantly obstructive sleep apnoea and
hypopnoea. The median central apnoea index was 0.4 (IQR
0.0–1.1). Nine patients had a few episodes of Cheyne–Stoke
respiration, but none fulfilled the criteria for central sleep
apnoea.3
Of the 33 patients with (A+H)/h >30, 2 had sleep studies
before the RCT of CPAP use was started and another
dropped out before randomisation. Thus 30 patients were
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randomised—15 to CPAP treatment and 15 to conservative
treatment for SDB. In the CPAP group, 14 patients had first-
ever strokes. 4 had total anterior circulation infarct, 9 had
partial anterior circulation infarct, 2 had posterior circulation
infarct and 0 had intracerebral haemorrhage and lacunar
infarct. In the conventional group, 14 patients had first-ever
strokes. Four had total anterior circulation infarct, 7 had
partial anterior circulation infarct, 2 had lacunar infarct, one
had posterior circulation infarct and one had intracerebral
haemorrhage. The trial was terminated before we had
recruited our target of 80 patients because recruitment was
much more difficult than expected and funding ended.
Baseline data
Patients randomised to CPAP use were similar to those
allocated conservative treatment for SDB (table 1). The
median Stanford Sleepiness Score was 3 (IQR 1–4) and
median pre-stroke Epworth Sleepiness Score was 6 (IQR
3–11).
Outcome assessment
The primary outcome measurement occurred at 80 (5) days
after stroke in the CPAP group and at 79 (4) days in the
controls. Two patients died before this assessment, one from
each group; their Barthel Index and EADL at follow-up were
Figure 1 Flow chart of patient recruitment and randomisation. AHI, apnoeas and hypopnoeas per hour; CPAP, continuous positive airway pressure;
NIH, National Institutes of Health; RCT, randomised controlled trial.
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scored as 0 and other scales were not scored. One patient
from the controls agreed only to telephone interview so
results of the National Institutes of Health Stroke Score, ACE
and Mini-Mental State Examination, which need face-to-face
assessment, were not available.
We found no significant differences in outcome with
respect to any of the primary or secondary measures at the
3-month follow-up (p.0.1, table 2).
Retrospective exploratory analyses showed that patients
randomised to CPAP use had significantly lower scores on the
mobility subscale of EADL (p = 0.048). However, they also
tended to have lower Barthel Index at baseline. Having
adjusted for baseline imbalance by multivariate analysis, this
difference in the mobility subscale was not significant
(p = 0.077). The CPAP group also had significantly lower
scores in the physical summary score of the Short Form 36
Health Survey (p = 0.022). This difference remained even
after adjusting for baseline imbalance (p = 0.008). At
6 months after stroke, there was no difference between the
CPAP group and the controls (table 3).
Ambulatory blood pressure monitoring
We found no significant difference in 24-h, daytime and
night-time systolic blood pressure, diastolic blood pressure
and mean arterial pressure between the CPAP group and
controls. Systolic blood pressure over 24 h was 126.2 (21.5)
and 130.0 (18.4) mm Hg and diastolic blood pressure was
71.6 (6.7) and 73.7 (12.3) mm Hg in the CPAP group and
controls, respectively (table 4; p.0.4).
Compliance with nasal CPAP use
Despite intensive education and encouragement, only 7 of 15
patients who were randomised to CPAP use kept the machine
Table 1 Baseline data in the continuous positive airway pressure treatment group
(n = 15) and controls (n = 15)
DOI Control CPAP
Age, years* 73 (65–77) 74 (73–81)
Male:female, n 9:6 11:4
BMI, kg/m2* 25.1 (22.1–33.1) 26.8 (21.9–28.5)
Systolic BP, mm Hg 164 (39) 151 (30)
Diastolic BP, mm Hg 87 (11) 85 (14)
(A+H)/h* 47.7 (36.5–60.2) 43.1 (35.6–51.8)
DI, n/h* 25.5 (7.0–40.3) 15.8 (8.1–22.7)
% time SaO2,90%* 3 (0.9–10.0) 4.9 (2.1–20.9)
ESS (0–24)* 2 6 (2–10) 6 (4–14)
SSS (1–7)* 2 3 (1–4) 2 (2–3)
NIHSS (0–42)* 2 6 (5–8) 5 (4–9)
BI (0–20)* + 14 (9–17) 11 (7–16)
HADS total (0–42)* 2 7 (5–15) 10 (6–15)
Anxiety (0–21)* 2 4 (2–5) 5 (2–6)
Depression (0–21)* 2 5 (3–9) 5 (2–9)
ACE (0–100)* + 79 (61–85) 84 (69–88)
ACE, Addenbrooke’s Cognitive Examination; (A+H)/h, total number of apnoeas and hypopnoeas per hour in bed;
BI, Barthel Index; BMI, body mass index; BP, blood pressure; CPAP, continuous positive airway pressure; DI,
desaturation index; DOI, direction of improvement: +, better status with higher scores, 2, worse status with higher
scores; ESS, Pre-stroke Epworth Sleepiness Scale; HADS, Hospital Anxiety and Depression Scale; NIHSS, National
Institutes of Health Stroke Scale; SaO2, arterial oxygen desaturation; SSS, Stanford Sleepiness Scale.
*Values are median (interquartile range).
Values are mean (SD).
Table 2 Outcome measurement in the continuous positive airway pressure treatment group and controls at 3 months (post-
treatment phase)
DOI n Control n CPAP Effect size p Value
EADL total (0–66) + 15 30 (16–41) 15 18 (11–27) 0.229
Mobility (0–18) + 15 6 (4–13) 15 3 (1–6) 20.72* 0.048
Kitchen (0–15) + 15 12 (4–14) 15 8 (1–13) 0.317
Domestic (0–15) + 15 1 (0–5) 15 0 (0–9) 0.822
Leisure (0–18) + 15 8 (6–9) 15 6 (5–8) 0.251
SSS (0–7) 2 14 2 (1–3) 14 3 (1–4) 0.119
BI (0–20) + 15 19 (16–20) 15 17 (14–18) 0.166
NIHSS (0–42) 2 13 3 (1–6) 14 2 (1–4) 0.622
MMSE (0–30) + 13 29 (25–30) 14 29 (25–29) 0.980
ACE (0–100) + 13 88 (74–90) 14 86 (75–91) 0.827
HADS total (0–42) 2 14 7 (3–10) 14 9 (6–13) 0.249
Anxiety (0–21) 2 14 3 (1–5) 14 3 (2–5) 0.981
Depression (0–21) 2 14 4 (3–5) 14 5 (4–9) 0.236
SF-36 Physical summary (0–100) + 14 30.8 (25.3–42.6) 14 23.7 (18.5–26.1) 20.85* 0.022
SF-36 Mental summary (0–100) + 14 56.4 (48.3–61.1) 14 49.8 (39.0–60.2) 0.232
ACE, Addenbrooke’s Cognitive Examination; (A+H)/h, total number of apnoeas and hypopnoeas per hour in bed; BI, Barthel Index; CPAP, continuous positive
airway pressure; DOI, direction of improvement: +, better status with higher scores, 2, worse status with higher scores; EADL, Extended Activities of Daily Living;
HADS, Hospital Anxiety and Depression Scale; MMSE, Mini-Mental Status Examination; NIHSS, National Institutes of Health Stroke Scale; SF-36, Short Form 36
Health Survey; SSS, Stanford Sleepiness Scale.
*p,0.05.
Values are median (interquartile range).
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for more than 4 weeks . The duration of CPAP treatment was
negatively correlated with the depression subscale score of
HADS (p = 0.039) and positively correlated with the language
subscale score of the ACE (p = 0.036) at baseline—that is,
better cognition and less depression were associated with
using the CPAP machine longer.
Among the 15 patients randomised to CPAP use, two
patients rejected CPAP after mask fitting and a brief trial in
the afternoon on day 1 of the treatment phase, one patient
rejected CPAP after the first night of CPAP use, one died of
adult respiratory distress syndrome on day 4 of the CPAP
limbs, and one rejected CPAP after 1 week of CPAP use.
Mean CPAP use in 15 patients was 1.4 h/night (median
0.16 h/night) when averaged over the 8-week treatment
period. Mean CPAP usage exceeded 6 h a night in only two
patients. The baseline data of five patients with better
compliance (>1 h, mean 3.8 (SD 2.8, range 1.0–7.3) h/night)
had mean (SD, range) (A+H)/h 46 (10, 36–58), body mass
index 29.3 (5.9, 21.8–38.1) kg/m2, Epworth Sleepiness Scale
6 (4, 3–14), Stanford Sleepiness Scale 2 (1, 1–3), National
Institute of Health Stroke Score 6 (4, 4–13) and Barthel Index
15 (6, 4–19). These were not significantly different from other
patients who were randomised (p.0.05).
Problems with CPAP use in the 15 patients were
categorised into the following four groups.
1. Problems with the machine: Eight patients had problems
with either mask or machine. Four of them abandoned
CPAP use quickly, including two who had claustrophobia.
2. Complications of CPAP use: Eight patients developed upper
airway symptoms after treatment and three of them
withdrew due to these symptoms.
3. Complications of stroke: Nine patients had stroke-related
problems that caused non-compliance, including facial
palsy, nocturnal confusion and involuntary movement
of head or wounds on the face due to falling down.
4. Lack of belief in treatment: Two patients did not think that
they needed CPAP on a nightly basis.
CPAP use was positively correlated with a better Barthel
Index (p = 0.035) and language subscale of ACE (p = 0.013),
but negatively correlated with depression subscale in HADS
(p = 0.032) at baseline. The median depression subscale of
the HADS in the five patients with better use (5, IQR 3–5)
was lower than in patients with poor use (7, IQR 3–10.5,
p = 0.031).
DISCUSSION
Our sleep studies confirm that SDB is common after acute
stroke and that most of the sleep-related breathing events are
obstructive.4 5 However, we were unable to show any
beneficial effect of CPAP treatment in patients in the
subacute phase of stroke.
We cannot exclude a clinically relevant benefit of CPAP use
in patients with stroke because we recruited fewer patients
than planned and thus our trial had insufficient power to
show anything other than large effects. Our failure to show
any effect of CPAP, either positive or negative, may also be
due to the poor use of CPAP in this trial.
CPAP use was poor despite our expertise in this area,29 30
our exclusion of many patients in whom we thought CPAP
use would be difficult, our use of auto-titrating CPAP which
may improve CPAP use in SDB,31 and the intensive input
from an experienced specialist sleep nurse (MV). Many of the
Table 4 Comparison of ambulatory blood pressure monitoring between the continuous positive airway pressure treatment
group and controls
Pressure (mm Hg) n Control* n CPAP* Mean difference (95% CI) p Value
24 h SBP 10 130.0 (18.4) 12 126.2 (21.5) 3.8 (214.2 to 21.8) 0.666
24 h DBP 10 73.7 (12.3) 12 71.6 (6.7) 2.1 (26.5 to 10.7) 0.618
24 h MAP 10 94.4 (13.0) 12 90.7 (11.4) 3.7 (27.2 to 14.5) 0.490
Day SBP 9 132.5 (20.2) 12 124.9 (22.6) 7.6 (212.3 to 27.6) 0.433
Night SBP 9 120.0 (18.8) 12 127.9 (22.7) 27.9 (227.4 to 11.6) 0.408
Day DBP 9 77.6 (14.6) 12 71.7 (8.0) 5.9 (24.5 to 16.4) 0.926
Night DBP 9 68.3 (12.2) 12 71.2 (7.0) 22.9 (211.7 to 5.9) 0.497
Day MAP 9 97.6 (16.0) 12 90.3 (12.5) 7.4 (25.6 to 20.4) 0.248
Night MAP 9 87.3 (13.0) 12 91.2 (12.2) 23.9 (215.5 to 7.7) 0.492
Day blood pressure recorded from 06:00 to 21:59; night blood pressure recorded from 22:00 to 05:59.
CPAP, continuous positive airway pressure; DBP, diastolic blood pressure; MAP, mean arterial blood pressure; SBP, systolic blood pressure.
*Values are mean (SD).
Table 3 Outcome measurements at 6 months after stroke in the continuous positive airway pressure treatment group and
controls
DOI n Control* n CPAP* Effect size p Value
EADL total (0–66) + 15 28 (18–39) 14 23 (12–33) 0.498
Mobility (0–18) + 15 6 (4–12) 14 4 (2–6) 20.53 0.053
Kitchen (0–10) + 15 9 (6–14) 14 11 (1–13) 0.930
Domestic (0–10) + 15 2 (0–7) 14 3 (0–7) 1.000
Leisure (0–18) + 15 7 (5–9) 14 8 (4–10) 0.912
BI (0–20) + 15 18 (16–19) 14 19 (11–20) 0.640
SF-36 Physical summary(0–100) + 13 28.4 (18.5–35.9) 13 19.8 (15.9–32.6) 0.248
SF-36 Mental summary(0–100) + 13 54.3 (39.7–61.3) 13 52.8 (43.2–58.9) 0.798
BI, Barthel Index; CPAP, continuous positive airway pressure; DOI, direction of improvement: +, better status with higher scores,2, worse status with higher scores;
EADL, Extended Activities of Daily Living; SF-36, Short Form 36 Health Survey.
*Values are median (interquartile range).
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patients were inpatients during the treatment phase. Of the
patients treated using CPAP, there were only two patients
who on most criteria would have been regarded as having
adequately used CPAP; of the five with ‘‘better use’’, the
other three used the treatment for only (2 h/day on average.
The two good compliers in CPAP group were relatively
younger (ages 65 and 73 years) and had less severe stroke
(Barthel Index 19 and 18 v 11). One had previously habitual
snoring, witnessed apnoea and unrefreshed sleep. Another
had previously unrefreshed sleep and mild excessive daytime
sleepiness (postprandial). Both of them might have pre-
existing obstructive sleep apnoea but their (A+H)/h was not
higher than that of the rest of the CPAP group (35.9 and 35.6
v 43.1) and their Epworth Sleepiness Scale was normal
(4 and 5). Compliance might be improved in future studies by
focusing on less depressed and cognitively less impaired
patients, but this would further reduce the generalisability of
any result. Focusing on sleepy patients would also be
interesting.
Compliance with CPAP after stroke has varied considerably
in previous studies.16 32–34 This variation is likely to reflect
differences in patient selection, environment in which
treatment is given, the CPAP system used and the amount
and type of support and training given.
Our study cannot support the recent studies,1 14 15 which
suggested that treatment for SDB reduces the risk of vascular
events. However, we studied unselected patients with stroke,
whereas all these studies were on populations with pre-
existing sleep apnoea.1 14 15 The only other RCT of CPAP use
after stroke included 59 patients randomised between 7 and
28 days after stroke to either CPAP treatment for 4 weeks or
conventional treatment.16 Outcomes were assessed at 7 and
28 nights, respectively. CPAP use had no effect on recovery
from stroke, but there were fewer depressive symptoms
among those treated with CPAP. Of the 31 patients, 16
(51.6%) used CPAP for .4 h/night, with a mean of 4.1 (SD
3.6, range 0–10.9). We found no improvement in depressive
symptoms nor was there any such trend in our data.
Similarly, we did not show any reduction in ambulatory
blood pressure with CPAP use, which was reported in one
non-RCT on 16 patients in which non-compliant patients
were used as controls.34
We found that the CPAP group had considerably lower
physical summary scores on Short Form 36 Health Survey
after treatment even after adjusting for baseline Barthel
Index. This may be due to chance given our multiple
testing, but we cannot exclude the possibility that CPAP
treatment might have a negative effect on certain aspects of
outcome.
Although the severity of upper airway obstruction is
associated with a worse functional outcome at 6 months
after stroke,10 at present we believe that CPAP should be used
only after stroke in those patients who satisfy the criteria for
the sleep apnoea–hypopnoea syndrome20 but have no
clinically noticeable dysphasia or depression. If improve-
ments in equipment or techniques that could increase CPAP
compliance in patients with stroke become available, then
further randomised studies of the potential benefits of CPAP
would be worthwhile.
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